Search research articles
Contact Us
Filters
Showing results (231-240 of 261) with videos related to
Page
of 27
Sort By:
Physical Review Letters
|
September 27, 2017
Impact of Modular Total Absorption Spectrometer measurements of β decay of fission products on the decay heat and reactor ν[over ¯]_{e} flux calculation
A Fijałkowska, M Karny, K P Rykaczewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Daniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
D E Rathkopf, M R Patel, A D Choudhury, et al.
Nature Medicine
|
February 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
Matthew D Galsky, Charlene Mantia, Michaela Bowden, et al.
Cancer
|
March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
Glenwood D Goss, Everett E Vokes, Michael S Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Amita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2025
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
M M Gounder, P Martin-Romano, A Italiano, et al.
Cancer
|
March 12, 2026
A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer
Gayle S Jameson, Denise J Roe, Erkut Borazanci, et al.
Cancer Research
|
June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Patricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
Page
of 27
Search research articles
Search
Showing results (231-240 of 261) with videos related to
Sort By:
Page
of 27
Physical Review Letters
|
September 27, 2017
Impact of Modular Total Absorption Spectrometer measurements of β decay of fission products on the decay heat and reactor ν[over ¯]_{e} flux calculation
A Fijałkowska, M Karny, K P Rykaczewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Daniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
D E Rathkopf, M R Patel, A D Choudhury, et al.
Nature Medicine
|
February 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
Matthew D Galsky, Charlene Mantia, Michaela Bowden, et al.
Cancer
|
March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
Glenwood D Goss, Everett E Vokes, Michael S Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2015
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Amita Patnaik, Paul Haluska, Anthony W Tolcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2025
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
M M Gounder, P Martin-Romano, A Italiano, et al.
Cancer
|
March 12, 2026
A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer
Gayle S Jameson, Denise J Roe, Erkut Borazanci, et al.
Cancer Research
|
June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
Patricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
Page
of 27